Oxford Biomedica Regulatory News (OXB)

Oxford Biomedica

Block listing Application

Oxford, UK - 01 April 2022: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy Group announces that applications have been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange for a block listing of 500,000 ordinary shares of 50 pence each (the "Ordinary Shares").

The Ordinary Shares are being reserved under a block listing and will be issued from time to time pursuant to the following schemes:

· OXB Long Term Incentive Plan (LTIP) (300,000 Ordinary Shares); and

· OXB Employee Share Option Scheme (ESOS) (200,000 Ordinary Shares).

It is expected that admission of the Ordinary Shares will become effective on 06 April 2022. The Ordinary Shares will rank pari passu in all respects with the Group's existing ordinary shares in issue.

-Ends-

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group. In January 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as a 20% owner. To date, Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com.